251 related articles for article (PubMed ID: 27815262)
1. p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.
Zhang J; Kong G; Rajagopalan A; Lu L; Song J; Hussaini M; Zhang X; Ranheim EA; Liu Y; Wang J; Gao X; Chang YI; Johnson KD; Zhou Y; Yang D; Bhatnagar B; Lucas DM; Bresnick EH; Zhong X; Padron E; Zhang J
Blood; 2017 Jan; 129(3):358-370. PubMed ID: 27815262
[TBL] [Abstract][Full Text] [Related]
2. A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice.
Rajagopalan A; Feng Y; Gayatri MB; Ranheim EA; Klungness T; Matson DR; Lee MH; Jung MM; Zhou Y; Gao X; Nadiminti KV; Yang DT; Tran VL; Padron E; Miyamoto S; Bresnick EH; Zhang J
J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 37847561
[TBL] [Abstract][Full Text] [Related]
3. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J
Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595
[TBL] [Abstract][Full Text] [Related]
4. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
[TBL] [Abstract][Full Text] [Related]
5. PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia-initiating cells.
Hu T; Morita K; Hill MC; Jiang Y; Kitano A; Saito Y; Wang F; Mao X; Hoegenauer KA; Morishita K; Martin JF; Futreal PA; Takahashi K; Nakada D
Blood; 2019 Aug; 134(7):614-625. PubMed ID: 31270104
[TBL] [Abstract][Full Text] [Related]
6. NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.
Xue L; Pulikkan JA; Valk PJ; Castilla LH
Blood; 2014 Jul; 124(3):426-36. PubMed ID: 24894773
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.
Brendel C; Teichler S; Millahn A; Stiewe T; Krause M; Stabla K; Ross P; Huynh M; Illmer T; Mernberger M; Barckhausen C; Neubauer A
PLoS One; 2015; 10(4):e0123181. PubMed ID: 25901794
[TBL] [Abstract][Full Text] [Related]
8. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.
Wang J; Liu Y; Li Z; Wang Z; Tan LX; Ryu MJ; Meline B; Du J; Young KH; Ranheim E; Chang Q; Zhang J
Blood; 2011 Jul; 118(2):368-79. PubMed ID: 21586752
[TBL] [Abstract][Full Text] [Related]
9. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
Xu J; Haigis KM; Firestone AJ; McNerney ME; Li Q; Davis E; Chen SC; Nakitandwe J; Downing J; Jacks T; Le Beau MM; Shannon K
Cancer Discov; 2013 Sep; 3(9):993-1001. PubMed ID: 23733505
[TBL] [Abstract][Full Text] [Related]
10. Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.
Wang J; Kong G; Liu Y; Du J; Chang YI; Tey SR; Zhang X; Ranheim EA; Saba-El-Leil MK; Meloche S; Damnernsawad A; Zhang J; Zhang J
Blood; 2013 Jun; 121(26):5203-7. PubMed ID: 23687087
[TBL] [Abstract][Full Text] [Related]
11. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.
Sachs Z; LaRue RS; Nguyen HT; Sachs K; Noble KE; Mohd Hassan NA; Diaz-Flores E; Rathe SK; Sarver AL; Bendall SC; Ha NA; Diers MD; Nolan GP; Shannon KM; Largaespada DA
Blood; 2014 Nov; 124(22):3274-83. PubMed ID: 25316678
[TBL] [Abstract][Full Text] [Related]
12. NRAS mutations in de novo acute leukemia: prevalence and clinical significance.
Dunna NR; Vuree S; Anuradha C; Sailaja K; Surekha D; Digumarti RR; Rao VR; Yadav SK; Reddy R; Vishnupriya S
Indian J Biochem Biophys; 2014 Jun; 51(3):207-10. PubMed ID: 25204082
[TBL] [Abstract][Full Text] [Related]
13. Preclinical efficacy of MEK inhibition in Nras-mutant AML.
Burgess MR; Hwang E; Firestone AJ; Huang T; Xu J; Zuber J; Bohin N; Wen T; Kogan SC; Haigis KM; Sampath D; Lowe S; Shannon K; Li Q
Blood; 2014 Dec; 124(26):3947-55. PubMed ID: 25361812
[TBL] [Abstract][Full Text] [Related]
14. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice.
Shing DC; Trubia M; Marchesi F; Radaelli E; Belloni E; Tapinassi C; Scanziani E; Mecucci C; Crescenzi B; Lahortiga I; Odero MD; Zardo G; Gruszka A; Minucci S; Di Fiore PP; Pelicci PG
J Clin Invest; 2007 Dec; 117(12):3696-707. PubMed ID: 18037989
[TBL] [Abstract][Full Text] [Related]
16. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K
Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920
[TBL] [Abstract][Full Text] [Related]
17. Anti-leukemic effects of simvastatin on NRAS
Jang J; Lee J; Jang JH; Jung CW; Park S
Mol Biol Rep; 2019 Dec; 46(6):5859-5866. PubMed ID: 31452046
[TBL] [Abstract][Full Text] [Related]
18. Cooperation of Dnmt3a R878H with Nras G12D promotes leukemogenesis in knock-in mice: a pilot study.
Shi X; Yang Y; Shang S; Wu S; Zhang W; Peng L; Huang T; Zhang R; Ren R; Mi J; Wang Y
BMC Cancer; 2019 Nov; 19(1):1072. PubMed ID: 31703632
[TBL] [Abstract][Full Text] [Related]
19. Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.
Kunimoto H; Meydan C; Nazir A; Whitfield J; Shank K; Rapaport F; Maher R; Pronier E; Meyer SC; Garrett-Bakelman FE; Tallman M; Melnick A; Levine RL; Shih AH
Cancer Cell; 2018 Jan; 33(1):44-59.e8. PubMed ID: 29275866
[TBL] [Abstract][Full Text] [Related]
20. First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia.
Cho H; Shin I; Ju E; Choi S; Hur W; Kim H; Hong E; Kim ND; Choi HG; Gray NS; Sim T
J Med Chem; 2018 Sep; 61(18):8353-8373. PubMed ID: 30153003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
